Overexpression of 14-3-3θ promotes tumor metastasis and indicates poor prognosis in breast carcinoma

Oncotarget

Volumn 5, Issue 1, 2014, Pages 249-257

  Li, Nanlin ^a   Wang, Hui ^a   Fan, Jing ^a   Tong, Chao ^a   Yang, Jixin ^a   Wei, Hongliang ^a   Yi, Jun ^a   Ling, Rui ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

14 3 3 ; Breast Cancer; Metastasis; Prognosis

Indexed keywords

PROTEIN 14 3 3;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MIDDLE AGED; MOUSE; NONHUMAN; OVERALL SURVIVAL; PLASMID; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST TUMOR; CELL GROWTH; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SECONDARY; TUMOR RECURRENCE; XENOGRAFT;

14-3-3 PROTEINS; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; FEMALE; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS;

EID: 84893856580     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1502     Document Type: Article

References (22)

1. Zhao J, Meyerkord CL, Du Y, Khuri FR, Fu H. 14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol. 2011; 22(7):705-12.
2. Obsil T and Obsilova V. Structural basis of 14-3-3 protein functions. Semin Cell Dev Biol. 2011; 22(7):663-72.
3. Gardino AK and Yaffe MB. 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol. 2011; 22(7):688-95.
4. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C, Rapp UR, Rudel T. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol. 2005; 7(8):837-43.
5. Dong S, Kang S, Gu TL, Kardar S, Fu H, Lonial S, Khoury HJ, Khuri F, Chen J. 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. Blood. 2007; 110(1):360-9.
6. Saha M, Carriere A, Cheerathodi M, Zhang X, Lavoie G, Rush J, Roux PP, Ballif BA. RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MA -PK activation.Biochem J. 2012 ; 447(1):159-66.
7. Chen YC, Chu LY, Yang SF, Chen HL, Yet SF, Wu KK. Prostacyclin and PPARa agonists control vascular smooth muscle cell apoptosis and phenotypic switch through distinct 14-3-3 isoforms. PLoS One. 2013; 8(7):e69702.
8. Yan Y, Xu Y, Gao YY, Zong ZH, Zhang Q, Li C, Wang HQ. Implication of 14-3-3ε and 14-3-3θ/τ in proteasome inhibition-induced apoptosis of glioma cells. Cancer Sci. 2013; 104(1):55-61.
9. Lau JM, Jin X, Ren J, Avery J, DeBosch BJ, Treskov I, Lupu TS, Kovacs A, Weinheimer C, Muslin AJ. The 14-3-3tau phosphoserine-binding protein is required for cardiomyocyte survival. Mol Cell Biol. 2007; 27(4):1455-66.
10. Wang B, Liu K, Lin FT, Lin WC. A role for 14-3-3 tau in E2F1 stabilization and DN- A damage-induced apoptosis. J Biol Chem. 2004; 279(52):54140-52.
11. Slone SR, Lesort M, Yacoubian TA. 14-3-3theta protects against neurotoxicity in a cellular Parkinson's disease model through inhibition of the apoptotic factor Bax. PLoS One. 2011; 6(7):e21720.
12. Hodgkinson VC, ELFadl D, Agarwal V, Garimella V, Russell C, Long ED, Fox JN, McManus PL, Mahapatra TK, Kneeshaw PJ, Drew PJ, Lind MJ, Cawkwell L. Proteomic identifification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? J Proteomics. 2012; 75(4):1276-83.
13. Wang B, Liu K, Lin HY, Bellam N, Ling S, Lin WC. 14-3-3Tau regulates ubiquitin independent proteasomal degradation of p21, a novel mechanism ofp21 downregulation in breast cancer. Mol Cell Biol. 2010; 30(6):1508-27.
14. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer. 2003; 3(12):931-43.
15. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 protein as potential oncogenes. Semin Cancer Biol. 2006; 16(3):203-13.
16. Yan Y, Xu Y, Gao YY, Zong ZH, Zhang Q, Li C, Wang HQ. Implication of 14-3-3ε and 14-3-3θ/τ in proteasome inhibition-induced apoptosis of glioma cells. Cancer Sci. 2013; 104(1):55-61.
17. Bergamaschi A, Frasor J, Borgen K, Stanculescu A, Johnson P, Rowland K, Wiley EL, Katzenellenbogen BS. 14-3-3ζ as a predictor of early time to recurrence and distant metastasis in hormone receptor-positive and -negative breast cancers. Breast Cancer Res Treat. 2013; 137(3):689-96.
18. Hodgkinson VC, Agarwal V, ELFadl D, Fox JN, McManus PL, Mahapatra TK, Kneeshaw PJ, Drew PJ, Lind MJ, Cawkwell L. Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. J Proteomics. 2012; 75(9):2745-52.
19. Hodgkinson VC, ELFadl D, Agarwal V, Garimella V, Russell C, Long ED, Fox JN, McManus PL, Mahapatra TK, Kneeshaw PJ, Drew PJ, Lind MJ, Cawkwell L. Proteomic identifification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? J Proteomics. 2012; 75(4):1276-83.
20. Madaio RA, Spalletta G, Cravello L, Ceci M, Repetto L, Naso G. Overcoming endocrine resistance in breast cancer. Curr Cancer Drug Targets. 2010; 10(5):519-28.
21. Brinkman JA, El-Ashry D. ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia. 2009; 14(1):67-78.
22. Vazquez A, Grochola LF, Bond EE, Levine AJ, Taubert H, Müller TH, Würl P, Bond GL. Chemosensitivity profifiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.Cancer Res. 2010; 70(1):172-80.